Akari Therapeutics appoints Abizer Gaslightwala President and CEO; Samir Patel steps down effective April 14, 2025

Akari Therapeutics Plc

Abizer Gaslightwala appointed President and CEO effective ~April 21, 2025; prior SVP at Jazz Pharmaceuticals.
Annual base salary $475,000, target cash bonus of 50% base; time-based option for 1,100,000 ADS (4-yr vest).
Performance-based option for 600,000 ADS vests upon: ≥$15M financing or ≥$10M upfront ADC license by Dec 31, 2025.
Samir Patel steps down as CEO effective April 14, 2025, remains on Board; separation terms pending.
New CEO's employment includes non-compete on ADC-focused biopharma for 12 months post-employment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.